Akums Drugs & Pharmaceuticals recently achieved a significant milestone by obtaining the Good Manufacturing Practice (GMP) Certification from the Eurasian Economic Union (EAEU) for its hormonal manufacturing plant. This accomplishment opens up new avenues for the company to expand its reach into regulated international markets and reinforces the trust in its manufacturing capabilities.
The demand for hormonal therapies is on the rise in the EAEU region, with countries like Russia experiencing substantial growth in sales of contraceptive and hormone replacement products. The steady increase in demand for these products can be attributed to factors such as heightened awareness of reproductive health, government initiatives promoting healthcare reforms, and a shift towards modern family-planning methods.
The EAEU, comprising a population of over 180 million, presents lucrative opportunities for pharmaceutical companies that can ensure the consistent supply of reliable, affordable, and compliant hormonal products. Akums, with its newly acquired EAEU GMP certification, is strategically positioned to cater to this growing demand for oral hormonal dosage forms in the region.
Regulatory Approval and Market Potential
The GMP certification obtained by Akums covers the manufacturing of hormonal tablets for oral administration, targeting therapeutic areas like women’s health and endocrinology. These formulations encompass a wide range of products, including combined oral contraceptives, progestin-only pills, and hormone replacement therapy tablets, addressing various health conditions from contraception to hormonal deficiencies and menopausal symptoms.
The certification enables Akums to introduce its standardized and compliant hormonal products across all five EAEU member states, including Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan. The company is already in the process of registering selected products in Russia and Kyrgyzstan, with plans to extend its market presence to the remaining member states in the near future.
In India, the stringent regulations under the Drugs & Cosmetics Act, 1940, and Schedule M necessitate dedicated facilities for the manufacture of hormonal preparations due to their potency and the associated risks of cross-contamination. Akums has been compliant with these regulations since 2010, operating a specialized hormonal plant equipped with independent HVAC, air handling, and personnel flow systems.
Strategic Opportunities and Partnerships
With the EAEU GMP certification in place, Akums can now explore collaborative opportunities in contract manufacturing (CDMO) and direct supply agreements with partners in the region. The certification provides the company with the flexibility to engage in various business models, allowing it to adapt to the specific needs of its partners and clients.
Sandeep Jain, the Managing Director of Akums, expressed enthusiasm about the certification, highlighting the company’s commitment to meeting the growing demand for hormonal therapies in the EAEU region. He emphasized Akums’ capability to combine large-scale manufacturing capacity with consistently high-quality standards, positioning the company as a reliable provider of compliant hormonal formulations in the market.
Conclusion
The EAEU GMP certification marks a significant achievement for Akums Pharmaceuticals, paving the way for enhanced market access and growth opportunities in the Eurasian region. By aligning with regulatory expectations and focusing on strategic partnerships, Akums is poised to establish a strong foothold in the EAEU markets and contribute to meeting the healthcare needs of millions of individuals in the region.
Takeaways:
– Akums Pharmaceuticals’ EAEU GMP certification allows for expanded market access in the Eurasian region
– The demand for hormonal therapies is on the rise in EAEU countries, presenting significant growth opportunities
– Akums’ compliance with regulatory standards and focus on quality positions it as a reliable partner for hormonal products
– Strategic partnerships and flexible business models will drive Akums’ success in the EAEU market.
Read more on pharmabiz.com